HHS committed up to $4.9 million through ARPA-H to early ibogaine development work, and Compass Pathways says it has finished submitting its COMP360 psilocybin application to the FDA. Also this week: Senate report language on VA psychedelic planning, proposed DEA production quotas for 2027 and a California research solicitation for work with veterans.
The post Weekly Psychedelic Policy Briefing, Nov 13, 2026 appeared first on Psychedelics Today.


